Literature DB >> 1652278

Herpes simplex virus for gene delivery to neurons.

X O Breakefield1, N A DeLuca.   

Abstract

Vectors derived from herpes simplex virus provide a means of gene delivery to postmitotic neurons. The virus is readily taken up at nerve terminals, passes by rapid retrograde and anterograde transport within neurons, and is selectively transferred across synapses, thus allowing it entry from the periphery into the brain. This virus can enter a state of latency in some neurons, where it exists as an episomal element in the nucleus and is transcriptionally active to a reduced extent. In this state, the virus is apparently benign and can effect stable expression of foreign genes. The large (150 kb) genome of this double-stranded virus has been completely sequenced. Many of its 70 genes can be replaced while still allowing the virus to replicate in at least some cultured cells. Some mutations in the viral genome can compromise the toxicity of the virus and reduce or eliminate its ability to replicate within neurons. Many uses for herpes vectors can be envisioned, including evaluation of neuronal promoter elements and functions of neural proteins in culture and in vivo, as well as therapeutic delivery of genes to modulate nerve function and for gene replacement therapy in vivo.

Entities:  

Mesh:

Year:  1991        PMID: 1652278

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  18 in total

1.  A herpes simplex viral vector expressing green fluorescent protein can be used to visualize morphological changes in high-density neuronal culture.

Authors:  Torsten Falk; Lori A Strazdas; Rebecca S Borders; Ramsey K Kilani; Andrea J Yool; Scott J Sherman
Journal:  Electron J Biotechnol       Date:  2001-04-15       Impact factor: 2.800

2.  Projections of preBötzinger complex neurons in adult rats.

Authors:  Wenbin Tan; Silvia Pagliardini; Paul Yang; Wiktor A Janczewski; Jack L Feldman
Journal:  J Comp Neurol       Date:  2010-05-15       Impact factor: 3.215

3.  Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy.

Authors:  L N Johnson; G B Krohel; S D Allen; R Mozayeni
Journal:  J Natl Med Assoc       Date:  1996-06       Impact factor: 1.798

4.  Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity.

Authors:  X Danthinne; K Aoki; A L Kurachi; G J Nabel; E G Nabel
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  An enhanced packaging system for helper-dependent herpes simplex virus vectors.

Authors:  T A Stavropoulos; C A Strathdee
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 6.  The Gordon Wilson Lecture. In vivo gene therapy: a strategy to use human genes as therapeutics.

Authors:  R G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  1995

7.  Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector.

Authors:  K Mitani; F L Graham; C T Caskey; S Kochanek
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

8.  Improved cell survival by the reduction of immediate-early gene expression in replication-defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function.

Authors:  P A Johnson; M J Wang; T Friedmann
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Activity of the simian virus 40 early promoter-enhancer in herpes simplex virus type 1 vectors is dependent on its position, the infected cell type, and the presence of Vmw175.

Authors:  K Roemer; P A Johnson; T Friedmann
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery.

Authors:  M W Chang; T Ohno; D Gordon; M M Lu; G J Nabel; E G Nabel; J M Leiden
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.